Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2026

Inventory consisted of the following:

Prepaid expenses and other assets consisted of the following:


	June 30, 2026		December 31, 2025
Prepaid clinical costs	$	19,849	$	19,547
Interest receivable	9,566		7,758
Deferred compensation plan	5,906		3,249
Prepaid research and development costs	3,203		2,901
Prepaid subscriptions	2,447		1,255
Loyal preferred stock (see Note 7)	2,000		2,000
Other	4,714		3,456
Total prepaid expenses and other assets	47,685		40,166
Less prepaid expenses and other current assets	(23,144)		(17,839)
Prepaid expenses and other assets, net of current portion	$	24,541	$	22,327

Property and equipment, net consisted of the following:


	June 30, 2026		December 31, 2025
Leasehold improvements	$	10,139	$	10,003
Lab equipment	10,748		9,960
Office equipment	2,204		2,225
Computers and software	89		60
Property and equipment at cost	23,180		22,248
Less accumulated depreciation and amortization	(10,107)		(7,952)
Total	$	13,073	$	14,296

Accounts payable and accrued expenses consisted of the following:


	June 30, 2026		December 31, 2025
Accounts payable	$	13,248	$	22,611
Accrued clinical trial costs	10,213		7,369
Accrued outside services and professional fees	6,191		4,430
Accrued research and development costs	5,628		4,506
Accrued transaction-related costs (see Note 13)	2,281		—
Other accrued expenses	4,878		2,854
Total	$	42,439	$	41,770